Wolverine (BPC-157 + TB-500)
Why this combination
The 'Wolverine' stack pairs two of the most widely discussed repair peptides because their proposed mechanisms are complementary rather than redundant. BPC-157 is associated with angiogenesis and localized tendon/ligament/gut signaling, while TB-500 (a synthetic fragment of thymosin beta-4) is associated with actin regulation and cell migration across tissue.
Community protocols combine them during an acute recovery block on the theory that BPC-157 supports the local healing environment while TB-500 supports systemic cell migration to the injury site. Note that this combination rests almost entirely on animal data and anecdotal reports — there are no controlled human efficacy trials.
Per-compound dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| BPC-157 | 250–500 mcg | 1–2× daily | Often split AM/PM; community-derived. |
| TB-500 | 2–2.5 mg | 2× weekly (loading), then weekly | Loading phase ~4–6 weeks, then maintenance. |
Reconstitution math
For educational and research reference only. Not intended for human consumption, not medical advice. Compounds discussed are sold and used for laboratory research purposes only.
Separate vials
BPC-157 — reconstitute a 5 mg vial with 2 mL bacteriostatic water → 2,500 mcg/mL. A 250 mcg dose is 0.1 mL (10 units on a U-100 syringe); a 500 mcg dose is 0.2 mL (20 units).
TB-500 — reconstitute a 10 mg vial with 2 mL → 5,000 mcg/mL. A 2,500 mcg dose is 0.5 mL (50 units); a 2,000 mcg dose is 0.4 mL (40 units).
Pre-blended (single vial)
To run both from one vial: combine BPC-157 5 mg + TB-500 10 mg and add 3 mL bacteriostatic water.
This gives BPC-157 at 1,666.7 mcg/mL and TB-500 at 3,333.3 mcg/mL in the same solution. A single 0.3 mL draw (30 units) then delivers ~500 mcg BPC-157 and ~1,000 mcg TB-500 together.
Pre-blending is convenient but locks the two compounds to a fixed ratio — keep them separate if you want to titrate them independently.
Verify any blend with the reconstitution calculator before dosing — concentrations change for every compound when you alter the water volume.
Cycle length & alternatives
- Cycle length
- Typical community block: 4–6 weeks loading, optional 2–4 week taper/maintenance, then a break.
- Compared to alternatives
- Compared with BPC-157 alone, the stack adds TB-500's systemic cell-migration mechanism; compared with GLOW, it omits the cosmetic/skin angle of GHK-Cu. Evidence remains preclinical/anecdotal in all cases.
Sources & references
Frequently asked questions
Why are BPC-157 and TB-500 combined?
Their proposed mechanisms are complementary — BPC-157 with local angiogenesis/healing signaling, TB-500 with actin regulation and cell migration. The combination is community-driven and not supported by controlled human trials.
Can I keep them in one syringe?
Yes — see the pre-blended math above. The trade-off is a fixed dose ratio; keep them in separate vials if you want to adjust each one independently.
For educational and research reference only. Not intended for human consumption, not medical advice. Compounds discussed are sold and used for laboratory research purposes only.
Related stacks
GLOW (BPC-157 + TB-500 + GHK-Cu)
GLOW extends the Wolverine repair pairing with GHK-Cu, a copper-binding tripeptide associated with collagen synthesis, skin remodeling, and wound cosmesis. The idea is to combine systemic/structural repair (BPC-157 + TB-500) with a skin- and collagen-oriented signal (GHK-Cu).
KLOW (KPV + BPC-157 + TB-500 + GHK-Cu)
KLOW adds KPV — a tripeptide fragment of alpha-MSH with anti-inflammatory properties — to the GLOW stack, aiming to pair tissue/skin repair with an inflammation- and gut-oriented signal.